trending Market Intelligence /marketintelligence/en/news-insights/trending/ql8hjovz4kz4p_n2rpl7aq2 content esgSubNav
In This List

Nabriva Therapeutics prices ordinary share offering

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Nabriva Therapeutics prices ordinary share offering

Nabriva Therapeutics PLC priced an underwritten public offering of 18,181,818 ordinary shares at $2.75 per share.

The Dublin-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 2,727,272 ordinary shares at the same price.

The offer is expected to close on or about July 31. The company expects about $50 million in proceeds from the offering.

Morgan Stanley is acting as sole book-running manager for the offering, while Needham & Co., SunTrust Robinson Humphrey, and Wedbush PacGrow are acting as lead managers. Northland Capital Markets is acting as a manager for the offering.